Vicore Pharma Holding AB (publ) (STO:VICO)
Sweden · Delayed Price · Currency is SEK 10.90
0.00 (0.00%)
Sep 4, 2026, 5:29 PM CET
Vicore Pharma Holding AB Revenue
Vicore Pharma Holding AB had revenue of 2.21M SEK in the quarter ending June 30, 2026, with 26.75% growth. This brings the company's revenue in the last twelve months to 3.99M. In the year 2025, Vicore Pharma Holding AB had annual revenue of 3.82M, down -96.51%.
Revenue (ttm)
3.99M
Revenue Growth
-96.51%
P/S Ratio
768.31
Revenue / Employee
86.83K
Employees
46
Market Cap
3.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.82M | -105.53M | -96.51% |
| Dec 31, 2024 | 109.35M | - | - |
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 508.00K | -424.00K | -45.49% |
| Dec 31, 2017 | 932.00K | 80.00K | 9.39% |
| Dec 31, 2016 | 852.00K | 12.00K | 1.43% |
| Dec 31, 2015 | 840.00K | -11.00K | -1.29% |
| Dec 31, 2014 | 851.00K | 131.00K | 18.19% |
| Dec 31, 2013 | 720.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 424.56M |
| Hansa Biopharma AB | 189.46M |
| Genovis AB (publ.) | 136.99M |
| Oncopeptides AB | 95.15M |
| Egetis Therapeutics AB | 66.00M |
| BioInvent International AB | 32.51M |
| Medivir AB | 8.71M |
| Infant Bacterial Therapeutics AB | -1.00K |
Vicore Pharma Holding AB News
- 3 days ago - Vicore Pharma to Participate in Upcoming Healthcare Conferences - Accesswire
- 9 days ago - Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference - Accesswire
- 10 days ago - Vicore Pharma Holding AB Slides: Company presentation - Filings
- 11 days ago - Vicore Pharma to Present at the European Respiratory Society Congress 2026 - Accesswire
- 14 days ago - Vicore Pharma Holding AB Quarterly report: Q2 2026 - Filings
- 1 month ago - Vicore Pharma to Participate in the Leerink Therapeutics Forum - Accesswire
- 2 months ago - Vicore Pharma Holding AB Transcript: Status update - Transcripts
- 2 months ago - Vicore Pharma Holding AB Press release: Status update - Filings